Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer
Non-clear cell kidney cancer is a group of different subtypes [...]
Non-clear cell kidney cancer is a group of different subtypes [...]
The National Institute for Health and Care Excellence (NICE) has [...]
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
Yesterday is was announced that the Scottish Medicines Consortium (SMC) [...]
Late last week we learnt that the National Institute for [...]
The phase 2 KEYNOTE-B61 study was presented at the recent [...]
Results from the phase 3 CLEAR studywere presented at the [...]
The 2022 American Urological Association (AUA) Annual Meeting included a [...]
In this study, the health-related quality of life (HRQoL) of [...]
Adjuvant treatment is treatment that is given after surgery to [...]